CN117137917A - 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用 - Google Patents

纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用 Download PDF

Info

Publication number
CN117137917A
CN117137917A CN202311054107.XA CN202311054107A CN117137917A CN 117137917 A CN117137917 A CN 117137917A CN 202311054107 A CN202311054107 A CN 202311054107A CN 117137917 A CN117137917 A CN 117137917A
Authority
CN
China
Prior art keywords
compound
formula
liver
acid
nash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202311054107.XA
Other languages
English (en)
Chinese (zh)
Inventor
埃德温·Sc·吴
彼得·J·S·邱
许媺祺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TaiwanJ Pharmaceuticals Co Ltd
Original Assignee
TaiwanJ Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by TaiwanJ Pharmaceuticals Co Ltd filed Critical TaiwanJ Pharmaceuticals Co Ltd
Publication of CN117137917A publication Critical patent/CN117137917A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202311054107.XA 2016-04-22 2017-04-20 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用 Pending CN117137917A (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662326435P 2016-04-22 2016-04-22
US62/326,435 2016-04-22
US201662395436P 2016-09-16 2016-09-16
US62/395,436 2016-09-16
CN201780024846.0A CN109069503A (zh) 2016-04-22 2017-04-20 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用
PCT/US2017/028529 WO2017184819A1 (en) 2016-04-22 2017-04-20 Nalmefene, naltrexone or derivatives thereof for use in treating (non)-alcoholic steatohepatitis or non-alcoholic fatty liver disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780024846.0A Division CN109069503A (zh) 2016-04-22 2017-04-20 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用

Publications (1)

Publication Number Publication Date
CN117137917A true CN117137917A (zh) 2023-12-01

Family

ID=58668969

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780024846.0A Pending CN109069503A (zh) 2016-04-22 2017-04-20 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用
CN202311054107.XA Pending CN117137917A (zh) 2016-04-22 2017-04-20 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201780024846.0A Pending CN109069503A (zh) 2016-04-22 2017-04-20 纳美芬(nalmefene)、纳曲酮(naltrexone)或其衍生物在治疗(非)酒精性脂肪肝炎(nash)或非酒精性脂肪性肝病(nafld)的应用

Country Status (10)

Country Link
US (1) US10045977B2 (enExample)
EP (1) EP3445363A1 (enExample)
JP (1) JP2019514872A (enExample)
KR (1) KR20180129909A (enExample)
CN (2) CN109069503A (enExample)
AU (1) AU2017253228B2 (enExample)
BR (1) BR112018071705A2 (enExample)
CA (1) CA3021788C (enExample)
RU (1) RU2717677C1 (enExample)
WO (1) WO2017184819A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140441A2 (en) 2010-05-06 2011-11-10 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
JP6687544B2 (ja) 2014-05-28 2020-04-22 チルドレンズ ホスピタル メディカル センター 前駆細胞を指向性分化によって胃組織に変換するための方法及びシステム
US11584916B2 (en) 2014-10-17 2023-02-21 Children's Hospital Medical Center Method of making in vivo human small intestine organoids from pluripotent stem cells
CN109415685B (zh) 2016-05-05 2023-07-04 儿童医院医疗中心 用于体外制造胃底组织的方法和与其相关的组合物
EP3484515A4 (en) * 2016-07-14 2020-06-17 Children's Hospital Medical Center METHOD FOR TREATING FIBROSE
SG11201903697WA (en) 2016-11-04 2019-05-30 Childrens Hospital Med Ct Liver organoid compositions and methods of making and using same
NZ753873A (en) 2016-12-05 2023-01-27 Children’S Hospital Medical Center Colonic organoids and methods of making and using same
WO2018191673A1 (en) 2017-04-14 2018-10-18 Children's Hospital Medical Center Multi donor stem cell compositions and methods of making same
JP2020536529A (ja) 2017-10-10 2020-12-17 チルドレンズ ホスピタル メディカル センター 食道組織および／または臓器組成物およびそれを作製する方法
EP3727394A4 (en) 2017-12-21 2021-09-08 Children's Hospital Medical Center DIGITALIZED HUMAN ORGANOIDS AND METHOD OF USING THEREOF
CA3106634A1 (en) 2018-07-26 2020-01-30 Children's Hospital Medical Center Hepato-biliary-pancreatic tissues and methods of making same
AU2019339410A1 (en) 2018-09-12 2021-04-15 Children's Hospital Medical Center Organoid compositions for the production of hematopoietic stem cells and derivatives thereof
JP7610533B2 (ja) 2019-05-31 2025-01-08 チルドレンズ ホスピタル メディカル センター 造血幹細胞の生成および拡大方法
AU2022394933A1 (en) 2021-11-18 2024-05-09 Inventage Lab Inc. Sustained-release injectable composition containing naltrexone and method for preparing same
CN118234488A (zh) 2021-11-18 2024-06-21 创技公司株式会社 包含难溶性药物的微粒的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437516A (zh) * 2004-09-08 2009-05-20 詹肯生物科学公司 使用纳美芬及其类似物治疗疾病
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086058A (en) * 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
MXPA04011327A (es) 2002-05-17 2005-08-15 Jenken Biosciences Inc Opioides y compuestos similares a opioides y usos de los mismos.
US8017622B2 (en) * 2003-05-16 2011-09-13 Jenken Biosciences, Inc. Opioid and opioid-like compounds and uses thereof
TR201002473A2 (tr) * 2010-03-31 2011-09-21 Mustafa Nevzat �La� Sanay�� A.�. Herpes zoster hastalığının bır opiat reseptör antagonist kullanılarak tedavi yöntemi.
CN102048733B (zh) 2010-12-23 2011-12-28 武汉同源药业有限公司 盐酸纳美芬在制备治疗脂肪肝的药物中的用途
EP3416619A2 (en) * 2016-02-18 2018-12-26 Immune Therapeutics, Inc. Method for inducing a sustained immune response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437516A (zh) * 2004-09-08 2009-05-20 詹肯生物科学公司 使用纳美芬及其类似物治疗疾病
US20150335638A1 (en) * 2009-07-16 2015-11-26 Mallinckrodt Llc (+)-morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof
CN105377246A (zh) * 2013-04-22 2016-03-02 卡迪拉保健有限公司 针对非酒精性脂肪性肝病(nafld)的新组合物

Also Published As

Publication number Publication date
WO2017184819A1 (en) 2017-10-26
JP2019514872A (ja) 2019-06-06
US20170304294A1 (en) 2017-10-26
CN109069503A (zh) 2018-12-21
AU2017253228A1 (en) 2018-09-27
AU2017253228A8 (en) 2019-01-17
CA3021788A1 (en) 2017-10-26
BR112018071705A2 (pt) 2019-02-19
US10045977B2 (en) 2018-08-14
AU2017253228B2 (en) 2020-04-09
RU2717677C1 (ru) 2020-03-25
KR20180129909A (ko) 2018-12-05
CA3021788C (en) 2021-08-03
EP3445363A1 (en) 2019-02-27

Similar Documents

Publication Publication Date Title
CN117137917A (zh) 纳美芬、纳曲酮或其衍生物在治疗(非)酒精性脂肪肝炎或非酒精性脂肪性肝病的应用
JP2019514872A5 (enExample)
AU2020267217B2 (en) Therapeutic methods employing noribogaine and related compounds
US10959963B2 (en) Method for the treatment of fatty liver disease
EP0146363B1 (en) Synergistic pharmaceutical compositions, their production and use
WO2016195355A1 (ko) 필버톤의 신규한 용도
JP2011524378A (ja) 糖尿病を治療するための医薬組成物
US20150306167A1 (en) Alpinia spp. extracts for treating irritable bowel syndrome
KR20220113411A (ko) KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
CN112020356B (zh) 作为抗疟疾药物组合的喹啉-4-甲酰胺类和苯并萘啶衍生物的组合
US20180318290A1 (en) Use of nalmefene in non-alcoholic steatohepatitis
JP6914256B2 (ja) 膵臓脂肪浸潤を予防または治療し、膵臓脂肪浸潤に起因する膵臓病変、糖尿病または他の関連症状を緩和するための組成物、および方法
WO2006034624A1 (fr) Procede pour la preparation d’une preparation de tetrodotoxine a base d’huile
TW201813646A (zh) 納美芬(nalmefene)在非酒精性脂肪肝炎(nash)的應用
CN103690535A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗肝纤维化药物中的应用
TW201625248A (zh) 用於胃輕癱之５－ｈｔ４受體激動劑
WO2019242764A1 (zh) 糖苷类化合物在制备防治糖尿病并发症的药物中的应用
KR20190130241A (ko) 크로몰린 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 지방간의 예방 또는 치료용 약학적 조성물
CN117700427A (zh) 一种daca及其制备方法、应用和药物组合物
TW201742628A (zh) 錫蘭七指蕨、入地蜈蚣素及黃酮類化合物用於治療或預防新陳代謝疾病之用途
WO2016152965A1 (ja) 低アルブミン血症の改善剤
CN121197128A (zh) 对乙酰氨基酚与非那西丁的组合物及其应用
HK1216614B (zh) 治疗脂肪肝疾病的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination